Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24346375 | 0.89 | POLB (0.35) | POLBLMNATP53ALDH1A1SMN1; SMN2 | |
| SCHEMBL23905515 | 0.89 | POLB (0.37) | POLBLMNATP53ALDH1A1SMN1; SMN2 | |
| SCHEMBL24345474 | 0.87 | POLB (0.35) | POLBLMNATP53ALDH1A1SMN1; SMN2 | |
| SCHEMBL29620737 | 0.86 | POLB (0.37) | POLBLMNATP53ALDH1A1MEN1 | |
| SCHEMBL24345846 | 0.86 | POLB (0.37) | POLBLMNATP53ALDH1A1MEN1 | |
| SCHEMBL24345453 | 0.85 | POLB (0.35) | POLBLMNAMEN1HPGDKMT2A | |
| SCHEMBL29620711 | 0.85 | POLB (0.35) | POLBLMNAMEN1HPGDKMT2A | |
| SCHEMBL24345268 | 0.85 | POLB (0.35) | POLBLMNAMEN1HPGDKMT2A | |
| SCHEMBL24345317 | 0.85 | POLB (0.34) | POLBLMNATP53ALDH1A1SMN1; SMN2 | |
| SCHEMBL24346374 | 0.84 | POLB (0.35) | POLBLMNATP53MEN1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220119398-A1 | HETEROCYCLIC COMPOUNDS AS ANTI-VIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220119398-A1 | HETEROCYCLIC COMPOUNDS AS ANTI-VIRAL AGENTS | VIP, ACE, FURIN | POLB 3294/4885LMNA 2322/4885TP53 2205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.